Silence Therapeutics Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-1.8%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.40next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly70.1MTarget: Sufficient to fund operations for at least 12 months
Quarterly Net Loss Quarterly-15MTarget: Narrowing loss through cost-discipline and completed Phase 3 readiness
Quarterly Research and Development (R&D) Expenses Quarterly9.1MTarget: Prudent investment focused on lead clinical assets
Watch Items
- Divesiran Phase 2 SANRECO Topline ResultsTrigger: Topline data release in polycythemia vera (PV)Action: Evaluate efficacy (hematocrit control <45% without phlebotomies) and safety profile to support registrational path.
- Zerlasiran Phase 3 Partnership AgreementTrigger: Execution of a co-development or licensing deal with a major pharmaceutical partnerAction: Assess upfront cash, milestone structures, and cost-sharing terms to mitigate Phase 3 financial risk.
- SLN312 Global Rights TransitionTrigger: AstraZeneca's formal return of exclusive global rights following Phase 1 completionAction: Review Phase 1 clinical data package and formulate internal development or alternative out-licensing strategy.
Research as of 20 Jun 2026